Contraline Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Contraline's estimated annual revenue is currently $3.4M per year.(i)
  • Contraline's estimated revenue per employee is $155,000

Employee Data

  • Contraline has 22 Employees.(i)
  • Contraline grew their employee count by 83% last year.

Contraline's People

NameTitleEmail/Phone
1
Co-Founder and CEOReveal Email/Phone
2
Chief Technology OfficerReveal Email/Phone
3
VP QualityReveal Email/Phone
4
Chief Medical OfficerReveal Email/Phone
5
Director Finance and Business DevelopmentReveal Email/Phone
6
Associate Manager, Preclinical StudiesReveal Email/Phone
7
Project ManagerReveal Email/Phone
8
Operations/HR/Finance ManagerReveal Email/Phone
9
Product Development ManagerReveal Email/Phone
10
Project Engineer IIIReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.4M9-10%N/AN/A
#2
$4.3M284%N/AN/A
#3
$1.1M70%N/AN/A
#4
$3.5M45-52%$56.5MN/A
#5
$0.3M20%N/AN/A
#6
$4.5M2921%N/AN/A
#7
$1.9M129%N/AN/A
#8
$7M455%N/AN/A
#9
$6.7M435%N/AN/A
#10
$2M13-13%N/AN/A
Add Company

What Is Contraline?

Contraline is a medical device company developing a long-lasting, non-hormonal, and reversible male contraceptive using advancements in hydrogel technology.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

83%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Contraline News

2022-03-30 - Contraline Appoints Medical Device Industry Leader Dr ...

... joins Contraline as Chief Technology Officer; Dr. Tropsha will spearhead efforts to bring Contraline's male contraceptive device, ADAM™,...

2022-03-22 - Male Birth Control Explained As New Pill 99 Percent Effective in Mice

ADAM is a birth control method being investigated by medical device company Contraline. It would work by injecting a gel into the vas...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.7M230%N/A
#2
$4.3M23-8%N/A
#3
$3.6M2344%N/A
#4
$3.3M23-12%N/A
#5
$2.9M24-8%N/A